[ad_1] Jay Geldmacher to retire as President and CEO, and member of the Board of Directors in 2025 Current Vice-Chair, Andrew C. Teich, to become Chairman SCOTTSDALE, Ariz., Nov. 7, 2024 /PRNewswire/ — Resideo Technologies, […]
Tag: Inc.
Rollins to Present at Upcoming Investor Conferences
[ad_1] ATLANTA, Nov. 7, 2024 /PRNewswire/ — Rollins, Inc. (NYSE:ROL) (“Rollins” or the “Company”), a premier global consumer and commercial services company, today announced that Kenneth Krause, Executive Vice President, Chief Financial Officer and Treasurer, […]
Onewheel Reimagines its Best-Selling XR Board, Adding Next-Gen Upgrades for a Drool-Worthy Retro Throwback
[ad_1] SANTA CRUZ, Calif., Nov. 7, 2024 /PRNewswire/ — Future Motion Inc., the maker of Onewheel, the iconic, self-balancing single-wheel electric board, is announcing the launch of the XR Classic, a reimagined version of its best-selling […]
Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference USA – English USA – English
[ad_1] Data show that Dragonfly’s DF6215 IL-2 cytokine drives greater therapeutic benefit in vivo than non-alpha IL-2, with no evidence of capillary leak syndrome or cytokine release syndrome . In addition, DF6215 synergizes with PD-1 […]
Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference
[ad_1] Data show that Dragonfly’s DF6215 IL-2 cytokine drives greater therapeutic benefit in vivo than non-alpha IL-2, with no evidence of capillary leak syndrome or cytokine release syndrome . In addition, DF6215 synergizes with PD-1 […]
